Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Bruce Sands MD, MS

Bruce E. Sands MD, MS

Dr. Burrill B. Crohn Professor of Medicine; Chief, Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, New York, New York

Bruce Sands, MD, MS, is the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, New York, and Chief of the Division of Gastroenterology of the Mount Sinai Health System.

Dr. Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. Dr. Sands was awarded his BA and MD from Boston University, and trained in internal medicine at the Hospital of the University of Pennsylvania. After completing GI fellowship at the Massachusetts General Hospital, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Dr. Sands is a past chair of the Clinical Research Alliance of the Crohn's & Colitis Foundation of America and served as Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, Dr. Sands was the Chair of the International Organization for the Study of IBD (IOIBD). In 2016 Dr. Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn’s & Colitis Foundation, that organization’s highest honor. In 2023, Dr. Sands was the recipient of the Jacobi Medallion, Mount Sinai’s highest award, given for distinguished contributions to the field of medicine or extraordinary service to the Hospital, Health System, School of Medicine, or alumni community.

Dr. Sands is widely recognized for his innovative treatment of Crohn’s disease and ulcerative colitis and for his expertise in the clinical investigation of new therapeutics. Dr. Sands' research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD in Rhode Island, a project funded by both the National Institute of Health and the Centers for Disease Control and Prevention. Dr. Sands has served as an Associate Editor for the journal Gastroenterology, and has published more than 300 original manuscripts in leading journals such as Gut, Gastroenterology, and the American Journal of Gastroenterology. He was the lead investigator of the landmark studies ACCENT 2, UNIFI and VARSITY, published in the New England Journal of Medicine, and SEAVUE, published in The Lancet.

Disclosures

Dr. Sands reports the following:
  • Honoraria for consulting
    • AbbVie
    • Amgen
    • AstraZeneca
    • Boehringer-Ingelheim
    • Bristol Myers Squibb
    • Celltrion
    • Fresenius Kabi
    • Genentech
    • Glaxo SmithKline
    • Janssen
    • Lilly
    • Merck & Co.
    • Pfizer
    • Takeda
    • Teva
  • Honoraria for speaking
    • AbbVie
    • Janssen
    • Pfizer
    • Takeda
    • Bristol Myers Squibb
    • Lilly
  • Stock Shareholder
    • Ventyx Biosciences
  • Research Support 
    • Janssen
    • Bristol Myers Squibb